A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Phase 3
Completed
- Conditions
- Psoriasis
- Registration Number
- NCT00096603
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
- Signed informed consent
- Previous participation in Study ACD2600g
- For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study
Exclusion Criteria
- Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method